Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
Interim data from a phase II study produced positive safety and efficacy data for bel-sar (belzupacap sarotalocan) for the first-line treatment of patients with early-stage choroidal melanoma. With an average of nine months of follow up, the interim data shows the evaluation of two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal route of administration.
In a study published in Cancer Immunology Research, researchers at Moffitt Cancer Center, led by Amer A. Beg, show how stimulating dendritic cells through the CD40 and interferon β pathways produces strong T-cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses.
The New York Proton Center has initiated three FLASH radiation therapy mouse model studies that will examine the use of FLASH RT to improve treatment of lung, pelvic, and abdominal tumors. NYPC researchers are conducting the studies in partnership with oncologists at Memorial Sloan Kettering Cancer Center, Montefiore Einstein Cancer Center, and Mount Sinai Health System.
Researchers at MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer, highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors. The study was published in Cancer Cell.
A study by New York University researchers, published this week in the journal Proceedings of the National Academy of Sciences, explains why cancers not only stop responding to kinase inhibitors but come back stronger, a finding that could inform which drugs oncologists use as a first-line treatment.
Gritstone bio Inc., entered into a clinical trial agreement with NCI to evaluate an autologous T-cell therapy expressing a T-cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a phase I study. The study will be led by Steven A. Rosenberg, chief of the surgery branch at NCI’s Center for Cancer Research.
MD Anderson Cancer Center and Xilis formed a strategic collaboration to use Xilis’ proprietary MicroOrganoSphere technology in support of preclinical research to accelerate the development of novel cancer therapies.
NCI is increasing the R01 payline to the 12th percentile in fiscal year 2023, up from the 11th percentile in FY22—bringing the institute’s payline to a level not seen since 2010.
One city is famous for its cheesesteaks. The other—a known hotspot for some of the country’s best barbecue.
